Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has announced the conversion of NOK 2,000,000 worth of convertible bonds into 3,265,661 new shares, increasing the company’s share capital to NOK 63,305,046.60. This conversion reflects Circio’s strategic financial maneuvers to bolster its capital structure, potentially enhancing its market position and stakeholder value.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for advanced gene and cell therapies. Their proprietary circVec platform enhances RNA, DNA, and viral therapeutics, offering significant improvements in RNA half-life and protein expression. Circio is also advancing its immuno-oncology program, TG01, targeting RAS-mutated cancers through collaborations.
YTD Price Performance: -11.83%
Average Trading Volume: 1,369,240
Current Market Cap: NOK64M
For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.